PMEF
LGND icon

Point72 Middle East FZE’s Ligand Pharmaceuticals LGND Stock Holding History

Point72 Middle East FZE’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$1.59K – 1836
2023
Q1 		$1.59K Buy
+22
New +$1.56K ﹤0.01% 1548

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Point72 Middle East FZE's LGND Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 22 shares — an estimated $1.59K sold.

Point72 Middle East FZE first reported a position in LGND in Q1 2023 and held it in 1 quarter. The position peaked at $1.59K in Q1 2023. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 22 Ligand Pharmaceuticals shares in Q2 2023, an estimated $1.59K.
  • Point72 Middle East FZE first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Ligand Pharmaceuticals position peaked at $1.59K in Q1 2023.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.